New sleeping pill may treat Alzheimer's

Share this article:

A new insomnia drug may be used for Alzheimer's and depression, according to its Japanese maker.

Takeda Pharmaceutical Co. Ltd., the Osaka-based drug manufacturer, could extend the use of Ramelteon -- a new sleeping pill to be released in the U.S. market in early fall -- to treat Alzheimer's disease and other illnesses. The new drug, which is in clinical trials in Japan and Europe, has a new mechanism that specifically targets the MT1 and MT2 receptors in the brain, which are critical in regulating the body's sleep-wake cycle.

The company filed for FDA approval for the drug last year and expects to gain approval with "non-scheduled drug" status, which means that no restrictions will be placed on how physicians prescribe the drug. It may start clinical development of the drug to treat Alzheimer's disease and depression after the pill's launch, the company announced.

Share this article:

More in News

Hospitals slap the government with lawsuits over 'two-midnight' policy to reduce observation stays

Hospitals slap the government with lawsuits over 'two-midnight' ...

The American Hospital Association and other hospital groups have sued the federal government over the so-called "two-midnight rule," which was designed in part to ease access to skilled nursing services. ...

Government would pay seniors to create advanced directives under Senate bill

Medicare beneficiaries would be paid to create advance directives and store them in an easy-access system if a recently proposed Senate bill were to become law.

MS patients less tense and pessimistic in nursing homes than at home, ...

Nursing home residents with severe multiple sclerosis report being less tense and pessimistic than similar individuals receiving care at home, according to recently published research findings.